Dockets Management Branch The Food and Drug Administration Department of Health & Human Services, Rm. 1-23 12420 Parklawn Dr. Rockville, MD 20857

Date: Oct 2. 1999

Re: 99P-1340/CP 1 — Petition to Have Eternity eau de parfum declared "Misbranded" UCT 12 /10:10

Dear Sir or Madam:

In May 1999, the Environmental Health Network (EHN) submitted the above petition to have Calvin Klein's Eternity eau de parfum declared "misbranded." I am writing because I fully support this petition and request that the FDA give it careful attention with regard to your regulations 21CFR Sec. 740.1, 21CFR Sec. 740.2, and 21CFR Sec. 740.10. Regulation 21CFR Sec. 740.10 states:

- · Each ingredient used in a cosmetic product and each finished cosmetic product shall be adequately substantiated for safety prior to marketing. Any such ingredient or product whose safety is not adequately substantiated prior to marketing is misbranded unless it contains the following conspicuous statement on the principal display panel:
- "Warning The safety of this product has not been determined."

As the petition shows, Eternity contains toxic ingredients and ingredients whose safety have not been substantiated. There is no warning label on its packaging.

We all have a right to know the status of safety testing of the ingredients in products such as Eternity so that we can protect ourselves and our families from toxic chemicals that may cause health problems. Most people are not aware that most fragrance materials have only limited safety testing. They wrongfully assume these products are safe to use in any setting and are surprised when people complain.

Like tobacco smoke, the harmful chemicals currently used in these products may affect the health of many people, including: people with asthma, chemical sensitivities, chronic fatigue, and other environmental illnesses. Children are particularly vulnerable to toxic chemicals found in products purchased and used by their parents, caregivers and teachers. When I am exposed to fragrance products I can experience any of the following symptoms based upon the chemical fragrance product I encounter:

	1 7 1 1		0 1				
O	asthma		double vision	0	incoherence		nausea
	anaphylaxis		ear pain		incontinence		nose bleeds
O	anxiety, restlessness		eczema		irritability	D	rashes
o	breathing difficulty		eyes, watery or dry		joint aches		seizures
o	bronchitis		fatigue		laryngitis		short-term mem. loss
<b>y</b>	can't concentrate	D/	flushing		lethargy	0	sinusitis
	coughing	<b>B</b>	headaches		Jymph nodes swell		sneezing
	depression	D	heart beat irregularity	D/	mood swings		sores, skin/mouth
<b>D</b>	disorientation	D'	hives		muscle pain/weakness		swallowing difficulty
O'	dizziness		hypertension		nasal congestion		tinnitus
o	other:						
Please act on behalf of the millions of people who have suffered physical illness and injury resulting from							

fragrance exposure at work, at school and in social settings. These toxic chemicals act as powerful barriers to people disabled by asthma and chemical sensitivities. Toxic chemicals in fragrances have already ruined countless lives. Thank you.

Sincerely,

ly, Plyn D. Brax will - starton mix. Pd. Jebanon



first, fold down





Attn: 99P-1340/CP 1

Dockets Management Branch
The Food and Drug Administration
Department of Health & Human Services, Rm. 1-23
12420 Parklawn Dr.
Rockville, MD 20857

1, fold up